Corn, B. W. & Feldman, D. B. Cancer statistics, 2025: a hinge moment for optimism to morph into hope?. CA Cancer J. Clin. 75, 7–9 (2025).
Conroy, T. et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548–4554 (2011).
Bear, A. S., Vonderheide, R. H. & O’Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788–802 (2020).
Macherla, S. et al. Emerging role of immune checkpoint blockade in pancreatic cancer. Int. J. Mol. Sci. 19, 3505 (2018).
Leinwand, J. & Miller, G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat. Immunol. 21, 1152–1159 (2020).
Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527–540 (2020).
Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).
Senturk, Z. N., Akdag, I., Deniz, B. & Sayi-Yazgan, A. Pancreatic cancer: emerging field of regulatory B-cell-targeted immunotherapies. Front. Immunol. 14, 1152551 (2023).
Tong, D.-N. et al. Characterization of B cell-mediated PD-1/PD-L1 interaction in pancreatic cancer patients. Clin. Exp. Pharmacol. Physiol. 47, 1342–1349 (2020).
Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).
Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056–2072 (2019).
Chamma, H., Vila, I. K., Taffoni, C., Turtoi, A. & Laguette, N. Activation of STING in the pancreatic tumor microenvironment: a novel therapeutic opportunity. Cancer Lett. 538, 215694 (2022).
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. & Kroemer, G. Trial watch: STING agonists in cancer therapy. Oncoimmunology 9, 1777624 (2020).
Wang, Y., Geller, A. E. & Yan, J. Unexpected Breg-NK crosstalk in STING agonist therapy. Cell. Mol. Immunol. 19, 1330–1332 (2022).
Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7–24 (2015).
Kaneda, M. M. et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).
Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317–330 (2003).
Zhao, H. Y. et al. An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment. Cell Chem. Biol. 32, 280–290 e214 (2025).
Song, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022).
Vanpouille-Box, C., Hoffmann, J. A. & Galluzzi, L. Pharmacological modulation of nucleic acid sensors—therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 18, 845–867 (2019).
Jneid, B. et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci. Immunol. 8, eabn6612 (2023).
Sun, X., Zhou, X., Lei, Y. L. & Moon, J. J. Unlocking the promise of systemic STING agonist for cancer immunotherapy. J. Control. Release 357, 417–421 (2023).
Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897 (2010).
Lu, Y. et al. Complement signals determine opposite effects of B cells in chemotherapy-induced immunity. Cell 180, 1081–1097 (2020).
Pan, B.-S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).
Li, W. et al. cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy. Sci. Transl. Med. 12, eaay9013 (2020).
Zhu, Y. et al. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019).
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).
Hopfner, K.-P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).
DeNardo, D. G., Andreu, P. & Coussens, L. M. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev. 29, 309–316 (2010).
Xiong, J., Wang, H. & Wang, Q. Suppressive myeloid cells shape the tumor immune microenvironment. Adv. Biol. 5, 1900311 (2021).
Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799–820 (2022).
Werner, M., Hobeika, E. & Jumaa, H. Role of PI3K in the generation and survival of B cells. Immunol. Rev. 237, 55–71 (2010).
Olayinka-Adefemi, F., Hou, S. & Marshall, A. J. Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus. Front. Immunol. 14, 1115244 (2023).
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M. & Okkenhaug, K. PI3Kδ and primary immunodeficiencies. Nat. Rev. Immunol. 16, 702–714 (2016).
Beer-Hammer, S. et al. The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation. J. Leukoc. Biol. 87, 1083–1095 (2010).
Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3Kgamma in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687–700 (2022).
Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3Kγ in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687–700 (2022).
Lanahan, S. M. et al. PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells. Nat. Immunol. 25, 1422–1431 (2024).
Takeda, A. J. et al. Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nat. Commun. 10, 4364 (2019).
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.11–14.39.20 (2016).
Paster, E. V., Villines, K. A. & Hickman, D. L. Endpoints for mouse abdominal tumor models: refinement of current criteria. Comp. Med. 59, 234–241 (2009).
Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555–1577 (2010).
Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77–92 (1999).
Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178–193 (2018).
Grigorova, I. L., Panteleev, M. & Cyster, J. G. Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure. Proc. Natl Acad. Sci. USA 107, 20447–20452 (2010).
Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014).
Below, C. R. et al. A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. Nat. Mater. 21, 110–119 (2022).
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708–2721 (2013).
Li, C. et al. Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk. ACS Nano 18, 9584–9604 (2024).
Zhang, Y. et al. Small circular RNAs as vaccines for cancer immunotherapy. Nat. Biomed. Eng. 9, 249–267 (2025).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).